People: Prima BioMed Ltd (PBMD.OQ)

PBMD.OQ on NASDAQ Stock Exchange Global Market

2.20USD
4:00pm EDT
Price Change (% chg)

$-0.28 (-11.29%)
Prev Close
$2.48
Open
$2.45
Day's High
$2.45
Day's Low
$2.00
Volume
14,074
Avg. Vol
1,852
52-wk High
$6.96
52-wk Low
$2.00

Search Stocks

Summary

Name Age Since Current Position

Lucy Turnbull

 53 2010 Non-Executive Chairman of the Board

Matthew Lehman

 34 2012 Chief Executive Officer, Executive Director

Yue-Ling Wong

 2010 Non-Executive Deputy Chairman of the Board

Marc Voigt

 2012 Chief Financial Officer

Sharron Gargosky

 2012 Chief Technical Officer

Deanne Miller

 2012 General Counsel, Company Secretary

Neil Frazer

 55 2012 Chief Medical Officer

Richard Hammel

 2005 Non-Executive Director

Russell Howard

 60 2013 Non-Executive Director

Martin Rogers

 2012 Non-Executive Director
» Insider Trading

Biographies

Name Description

Lucy Turnbull

 Ms. Lucy H. Turnbull, AO, is Non-Executive Chairman of the Board of Prima Biomed Ltd since October 7, 2010. From 2001 to 2002, Ms. Turnbull was the Chairman of the New South Wales Government's Ministerial Advisory Committee on Biotechnology, from 2002 to 2006 she was a Director of the Sydney Cancer Foundation and from 1993 to 2000 she was Director and Chair of the Sydney Children's Hospital Foundation. She is currently on the Board of the Cancer Institute NSW. Ms. Turnbull also has experience in commercial legal practice and investment banking. During her career Ms. Turnbull has held a number of position including Lord Mayor of the City of Sydney from 2003 to 2004 and, prior to that, Deputy Lord Mayor of Sydney from 1999 to 2003. Ms. Turnbull is a Board member of Australian Technology Park at Redfern and the Sydney Metropolitan Development Authority. Ms. Turnbull is active in the not for profit sector and currently holds a number of positions including Deputy Chairman of the Committee for Sydney, and a board member of the U.S. Studies Centre at Sydney University, Biennale of Sydney, Cancer Institute NSW and the Redfern Foundation.

Matthew Lehman

 Mr. Matthew Lehman is Chief Executive Officer and Executive Director of Prima Biomed Ltd. Mr. Lehman was appointed as a director in May 2012. Mr. Lehman joined Prima as Chief Operating Officer in February 2010. He has played a role in the clinical development of Cvac as well as the executive management of the company. Prior to joining Prima BioMed, he was the Chief Operating Officer for SPRI Clinical Trials, an international contract research organization servicing the biotechnology and pharmaceutical industries, where he led the expansion of the business in the emerging Eastern European markets. Over the years, Mr. Lehman has held various positions of increasing responsibility in clinical development and biotechnology operations, with experience managing teams across the United States and Europe. He has been involved in hundreds of R&D programs in oncology and other therapeutic areas, including key development contributions to a number of now FDA- and EMA-approved products. Mr. Lehman is active in a number of industry organizations with a interest in optimizing clinical research and efficient deployment of R&D expenditures.

Yue-Ling Wong

 Mr. (Albert) Yue-Ling Wong is Non-Executive Deputy Chairman of the Board of Prima Biomed Ltd since October 7, 2010. He became Non-Executive acting Chairman of the Board of Directors in July 2010 and served in that position until being appointed to his current position in October 2010. Mr. Wong is a corporate adviser and investment banker with more than 29 years in the finance industry and brings his experience to the Board of Prima. Formerly a stockbroker for 22 years, Mr. Wong was admitted as a Member of the Australian Stock Exchange in 1988 and was a principal of Intersuisse Limited until 1995 when he established and listed on ASX the Barton Capital group of companies including eStar Online. Mr. Wong was also a founding Director of both Pluton Resources Limited and Gujarat NRE Resources NL. He is also involved in a number of philanthropic activities, these include current Directorships on UNSW Foundation Limited, Ian Thrope's Fountain for Youth Foundation, Honorary Life Governor and Vice President of the University of Sydney Physics Foundation. Mr. Wong remains a Fellow of the Financial Services Institute of Australasia, he is a Practitioner Member (Master Stockbroking) of the Stockbrokers Associations of Australia and a Fellow of the Australian Institute of Company Directors.

Marc Voigt

 Mr. Marc Voigt is Chief Financial Officer of Prima Biomed Ltd effective November 16, 2012. He was previously Chief Business Officer of the Company. Mr. Voigt has experience in the corporate and biotechnology sectors. He joined Prima BioMed's management team in 2011 as the General Manager of European operations at Prima BioMed GmbH. He has previously worked as an investment manager for Allianz Insurance biotech venture fund, and as a personal assistant to a member of the Executive Board of Allianz Insurance. Mr. Voigt has also worked for German investment bank, net.IPO.AG, in the area of business development and German securities offerings. In the biotech sector, he has held the positions of CFO/CBO at Revotar Biopharmaceuticals AG and Medical Enzymes AG. He has a Masters Degree in Business Administration from the Freie Universität of Berlin, and is a member of the pharma licensing club Germany and a member of the judging panel of Germany's business plan competition.

Sharron Gargosky

 Dr. Sharron Gargosky is Chief Technical Officer of Prima Biomed Ltd. Dr. Gargosky has 18 years' experience in the biotechnology and pharmaceutical industries, and has worked in senior positions in organizations that have received FDA approval for orphan drugs. She is responsible for managing the clinical team working on the Cvac immunotherapy cancer vaccine. Prior to joining Prima BioMed, Dr. Gargosky was a member of ILMU consulting LLC, where she provided project management and operational experience on pharmaceutical drug and biologic development-from early research to Phase IV Trials and the FDA approval process. Dr. Gargosky has also previously held the positions of Chief Scientific Officer at Pulse Health LLC in Portland in the USA, and Chief Scientific Officer and Senior Vice President of Corporate Development at Hyperion Therapeutics Inc. in San Francisco. At Ucyclyd Pharma she managed the approval of orphan drug products (Ammonul) and the development of the NCE, and within Medics Pharmaceuticals, a BLA submission and approval for Reloxin. As Vice President of Business Development for Diagnostic System Laboratories she was responsible for business expansion through evaluation and implementation of new growth opportunities and patent portfolio management. Dr. Gargosky has a Postdoctoral Fellowship in Pediatric Endocrinology from Stanford University in California, a Ph.D in biochemistry from University of Adelaide in Australia (in collaboration with CSIRO Divisions of Human Nutrition, South Australia), First Class Honors in Biochemistry from University of Adelaide, and a Bachelor of Science, Biochemistry (Distinction), Microbiology, Immunology & Virology (Distinction) from University of Adelaide.

Deanne Miller

 Ms. Deanne Miller, LLB is General Counsel and Company Secretary of Prima BioMed Ltd. She earned her LLB (Hons) and BCom (finance and accounting double major) from the University of Sydney. She brings experience in corporate law, tax, and regulatory compliance, having held various positions of increasing responsibility at organizations such as KPMG, Westfield Group, Australian Securities and Investments Commission (ASIC), Macquarie Group, and Westpac Group.

Neil Frazer

 Dr. Neil Frazer was Chief Medical Officer of Prima Biomed Ltd from February 1, 2010 to June 30, 2013. Dr. Frazer has more than 24 years experience in the pharmaceutical industry, including 10 years experience in oncology drug development, and has experience in managing the clinical development process of new drug applications. He has been involved in the applications for 10 new chemical entities in multiple therapeutic areas, plus more than 20 applications for line extensions of pharmaceutical drug applications. Dr. Frazer has a Bachelor of Medicine and Bachelor of Surgery (MB ChB) from the University of Edinburgh Medical School, and has a Fellowship from the Royal College of Anaesthetists in London (FRCA) and a Fellowship in Pharmaceutical Medicine from the Royal College of Physicians.

Richard Hammel

 Dr. Richard J. Hammel is Non-Executive Director of Prima Biomed Ltd since January 24, 2005. He holds BPharm, MSc, PhD. Dr Hammel is the founding partner of ProPharma International Partners in San Francisco, USA. ProPharma is a pharmaceutical/ biotechnology consulting firm providing a range of business, financial and product development services. He previously held senior management positions with Connetics Corporation (Vice President Business Development), Matrix Pharmaceuticals Inc (Vice President Business Development, Sales and Marketing) and held several positions at Glaxo Inc (Director, Professional Affairs; Director, New Business Development; and Director, Marketing Services). Dr. Hammel is widely recognized in the USA, Europe and Japan for his 30 years experience in commercialization and licensing in emerging and developing biotechnology companies.

Russell Howard

 Dr. Russell J. Howard, Ph.D., is Non-Executive Director of Prima Biomed Ltd since May 8, 2013. He is an Australian scientist, CEO, and entrepreneur; he was recently the overall winner of the 2013 Advance Global Australian Award for his global impact on the biotechnology field and green chemistry. After earning his Ph.D. in biochemistry from the University of Melbourne, Dr. Howard has held positions at a number of research laboratories around the world, including the Immunoparasitology Laboratory at the Walter & Eliza Hall Institute in Melbourne and the National Institutes of Health in Bethesda, Maryland where he became a tenured investigator. In industry, Dr. Howard worked at Schering-Plough’s DNAX Research Institute of Molecular and Cellular Biology in Palo Alto, California; was the President and Scientific Director of Affymax, Inc.; and was the co-founder and CEO of Maxygen, Inc. after its spin-out of Affymax-GlaxoWellcome. He also holds Bachelor of Science in Biochemistry and Bachelor of Science in Chemistry and Biochemistry from University of Melbourne.

Martin Rogers

 Mr. Martin Frederick Rogers is Non-Executive Director of Prima Biomed Ltd. Mr. Rogers, served as Chief Executive Officer from October 2007 to August 2012, and served as Managing Director from July 2010 to August 2012. Mr. Rogers has a science background and is currently a member of the management committee of the National Breast Cancer Foundation and a Council Member of the University of Sydney Physics Foundation. Mr. Rogers also has experience in the corporate sector, with a focus on the incubation and development of new business concepts and the establishment of internal ventures and external partnerships, including finance concept origination in the corporate banking sector for institutions such as Macquarie Bank.

Basic Compensation

Name Fiscal Year Total

Lucy Turnbull

 205,000

Matthew Lehman

 501,753

Yue-Ling Wong

 158,332

Marc Voigt

 167,154

Sharron Gargosky

 308,638

Deanne Miller

 --

Neil Frazer

 285,663

Richard Hammel

 117,723

Russell Howard

 --

Martin Rogers

 365,000
As Of 29 Jun 2012

Insider Trading

» Full list on Insider Trading
Search Stocks